Table 1.

Patient and Disease Characteristics and Baseline Laboratory Parameters

	All Patients (n = 66)
Patient characteristics
Male	32 (48.5)
Age (y)	39.5 (28.0, 54.0)
BMI	26.6 ± 5.1
Smoking
Former	23 (34.8)
Current	4 (6.1)
Prior UC-related hospitalization	27 (40.9)
UC-related arthropathy	14 (12.1)
Psoriatic arthritis	1 (1.5)
Psoriasis	11 (16.7)
Disease characteristics
Duration of disease (y)	6.0 (3.0, 15.0)
Extent of UC
Extensive colitis	40 (60.6)
Left-sided colitis	24 (36.4)
Proctitis	2 (3.0)
Baseline total Mayo Score	6.5 ± 2.4
No. with score ≥6 (moderate to severe disease)	45 (68.2)
Baseline partial Mayo score	4.1 ± 2.0
Baseline endoscopic subscore (n = 64)	2.3 ± 0.9
Laboratory parameters
WBC (103/µL)	8.7 ± 3.2
Hemoglobin (g/dL)	12.4 ± 1.7
Albumin (g/dL)	4.1 (3.9, 4.3)
CRP (mg/L) (n = 48)	4.8 (2.1, 15.3)
Fecal calprotectin (µg/g) (n = 9)	1000.0 (500.0, 1251.0)
Prior medications
Aminosalicylate	63 (95.5)
Corticosteroid	64 (97.0)
Immunomodulator (IMM)	37 (56.1)
TNF-antagonist	56 (84.8)
Prior use of ≥2 TNF antagonists	16 (24.2)
Combination therapy with IMM	17/56 (30.4)
Primary nonresponse	31/56 (55.3)
Secondary loss of response	17/56 (30.4)
History of anti-TNF antibodies	10/39 (25.6)
Vedolizumab	50 (75.8)
Tofacitinib	22 (33.3)
Prior use of any biologic or novel small molecule	61 (92.4)
Prior use of ≥2 biologics or novel small molecules	49 (74.2)
Mean no. prior biologics/novel small molecules	2.2 ± 1.2
Current medications
Aminosalicylate	16 (24.2)
Corticosteroid	23 (34.8)
Duration ≥3 months	12/23 (52.2)
Immunomodulator	8 (12.1)
TNF-antagonist	9 (13.6)
Vedolizumab	4 (6.1)
Tofacitinib	6 (9.1)

Proportions reported as no. (%). Continuous variables reported as mean ± SD, or median (IQR) when data not distributed normally.

CRP, C-reactive protein; WBC, white blood cell.